Table 4.
Aspirin/Ibuprofen Use and the Risk of Recurrent Colorectal Adenoma in the PLCO Cancer Screening Trial
| NSAID use (times/month) |
Controls | Recurrent Adenoma Overall | Advanced | Non-advanced | |||
|---|---|---|---|---|---|---|---|
| Cases | OR (95% CI)* | Cases | OR (95% CI)* | Cases | OR (95% CI)* | ||
| Aspirin ^ | |||||||
| <4 | 553 | 544 | 1.00 | 154 | 1.00 | 390 | 1.00 |
| 4 - <30 | 126 | 109 | 0.87 (0.64, 1.20) | 19 | 0.55 (0.31, 0.97) | 90 | 0.99 (0.71, 1.39) |
| ≥30 | 198 | 209 | 0.90 (0.69, 1.17) | 39 | 0.56 (0.36, 0.87) | 170 | 1.05 (0.79, 1.38) |
| P, trend | 0.47 | 0.006 | 0.63 | ||||
| Ibuprofen ^ | |||||||
| <4 | 736 | 737 | 1.00 | 185 | 1.00 | 552 | 1.00 |
| 4 - <30 | 77 | 68 | 0.87 (0.59, 1.27) | 10 | 0.55 (0.26, 1.15) | 58 | 0.94 (0.63, 1.40) |
| ≥30 | 64 | 57 | 1.15 (0.75, 1.77) | 17 | 1.31 (0.68, 2.54) | 40 | 1.07 (0.67, 1.72) |
| P, trend | 0.75 | 0.52 | 0.79 | ||||
| Combined use | |||||||
| <4 | 462 | 478 | 1.00 | 136 | 1.00 | 342 | 1.00 |
| 4 - <30 | 166 | 139 | 0.81 (0.61, 1.08) | 24 | 0.49 (0.29, 0.82) | 115 | 0.92 (0.68, 1.26) |
| 30 - <60 | 178 | 183 | 0.87 (0.66, 1.14) | 32 | 0.50 (0.31, 0.80) | 151 | 1.03 (0.77, 1.37) |
| ≥60 | 71 | 62 | 0.91 (0.59, 1.38) | 20 | 1.09 (0.58, 2.04) | 42 | 0.83 (0.52, 1.33) |
| P, trend | 0.29 | 0.06 | 0.69 | ||||
*
The Odds Ratio (OR) and 95% confidence interval (CI) were calculated by using unconditional logistic regression and adjusted for study center, race, sex, family history of colorectal cancer, smoking history, body mass index, age at baseline, number of follow-up colonoscopies, and follow-up time from baseline endoscopy
^
Aspirin use is adjusted for Ibuprofen use and vice versa